SMTNL2: A Potential Drug Target for Psychiatric Disorders (G342527)

Target Name: SMTNL2

NCBI ID: G342527

SMTNL2

SMTNL2: A Potential Drug Target for Psychiatric Disorders

Synaptophysin (SMTNL2) is a protein that is expressed in the nervous system and is known for its role in synaptic plasticity and neurotransmitter release. The exact function of SMTNL2 is not yet fully understood, but it is possible that it may be a drug target or biomarker for various neurological and psychiatric disorders.

SMTNL2 is a member of the synaptophysin family, which is a group of transmembrane proteins that are involved in the formation and maintenance of synapses, which are the structural and functional units of the nervous system. The family includes several different proteins, including SMTNL1, SMTN2 , and SMTN3, which are expressed in the brain and other nervous system tissues.

SMTNL2 is unique among the synaptophysin family because of its structure and localization. It is a transmembrane protein that is composed of four distinct domains: an N-terminus, a transmembrane domain, a cytoplasmic domain, and an C-terminus. The N-terminus is located at the end of the protein and is involved in the formation of the extracellular matrix (ECM), while the C-terminus is located at the beginning and is involved in the formation of the intracellular signaling complex. The transmembrane domain is located in the middle of the protein and is involved in the formation of the protein's unique structure and its ability to interact with other proteins.

SMTNL2 is known for its role in synaptic plasticity, which is the ability of the nervous system to change and adapt over time. Synaptic plasticity is critical for the development, learning, and memory of the nervous system. It is also involved in the regulation of neurotransmitter release, which is the process by which neurons transmit chemical signals with the help of neurotransmitters.

SMTNL2 is involved in the regulation of neurotransmitter release by interacting with the neurotransmitter-releasing channel, which is a protein called VGABR2. This channel is involved in the release of neurotransmitters from the axon terminal of nerve cells, and SMTNL2 is known to interact with VGABR2 in a way that regulates neurotransmitter release.

SMTNL2 is also involved in the regulation of neurotransmitter release by interacting with the protein called TrkB. TrkB is a G protein-coupled receptor that is involved in the regulation of neurotransmitter release. , which may have implications for the treatment of psychiatric disorders that are characterized by disruptions in neurotransmitter regulation.

SMTNL2 may also be a drug target for various psychiatric disorders. psychiatric disorders are a common cause of disability and are characterized by disruptions in neurotransmitter regulation. Disruptions in neurotransmitter regulation have been implicated in a wide range of psychiatric disorders, including depression, anxiety, and Schizophrenia.

SMTNL2 is thought to be a potential drug target for the treatment of psychiatric disorders because of its involvement in the regulation of neurotransmitter release. By interacting with the neurotransmitter-releasing channel VGABR2 and the protein TrkB, SMTNL2 may be involved in the regulation of neurotransmitter release. , which is a key aspect of the development and progression of psychiatric disorders.

In conclusion, SMTNL2 is a unique protein that is involved in the regulation of neurotransmitter release and is expressed in the nervous system. While the exact function of SMTNL2 is not yet fully understood, it is possible that it may be a drug target or biomarker for various psychiatric disorders. Further research is needed to fully

Protein Name: Smoothelin Like 2

The "SMTNL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMTNL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets